Skip to main content
SpringerLink
Log in

Zulassung von Idelalisib bei CLL und FL empfohlen

  • infopharm
  • Published:
Info Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Nach Information von GILEAD

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    red

Authors
  1. red
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

red Zulassung von Idelalisib bei CLL und FL empfohlen. Info Onkol. 17, 58 (2014). https://doi.org/10.1007/s15004-014-0960-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-014-0960-5

Search

Navigation